MMC safe after endocanalicular laser dacryocystorhinostomy

Multiple applications of mitomycin C proved to be largely safe and effective after endocanalicular laser dacryocystorhinostomy, a study found.

“Multiple postoperative applications of MMC delay the healing and subsequent closure of the osteotomy site, thereby increasing the success of the procedure,” the study authors said. “Careful monitoring of the nasal osteum is mandatory if postoperative application of MMC is contemplated.”

The prospective study included 125 endocanalicular laser dacryocystorhinostomy procedures performed on 114 patients diagnosed with primary acquired nasolacrimal duct obstruction. Mean patient age was 60 years.

A diode laser was used to perform all procedures. MMC was applied without irrigation intraoperatively and 1 week, 2 weeks and 3 weeks after surgery.

Mean follow-up was 14 months, with a minimum of 12 months. Primary outcome measures of success were resolution or improvement of epiphora, patency of the osteum, and presence or absence of complications resulting from the MMC application.

Study results at 12 months showed a success rate of 92.8%. All failures stemmed from cicatricial closure of the osteum and were identified 3 to 6 months postoperatively.

No significant intraoperative or postoperative nasal complications resulted from the application of MMC, the authors said.

Published by:

Sources/Disclosures

Collapse

Source:

Ophthalmic Plast Reconstr Surg. 2012;28(3):192-195.